Global effects of mistranslation from an editing defect in mammalian cells.

Aminoacyl-tRNA synthetases prevent mistranslation, or genetic code ambiguity, through specialized editing reactions. Mutations that disrupt editing in bacteria adversely affect cell growth and viability, and recent work in the mouse supports the idea that translational errors caused by an editing defect lead to a neurological disease-like phenotype. To further investigate the connection of mistranslation to cell pathology, we introduced an inducible transgene expressing an editing-deficient valyl-tRNA synthetase into mammalian cells. Introducing mistranslation precipitated a disruption of cell morphology and membrane blebbing, accompanied by activation of caspase-3, consistent with an apoptotic response. Addition of a noncanonical amino acid that is misactivated, but not cleared, by the editing-defective enzyme exacerbated these effects. A special ambiguity-detecting sensor provided direct readout of mistranslation in vivo, supporting the possibility that decreased translational fidelity could be associated with disease.

[1]  Manuel A. S. Santos,et al.  Selective advantages created by codon ambiguity allowed for the evolution of an alternative genetic code in Candida spp. , 1999, Molecular microbiology.

[2]  D. Yang,et al.  Cloning, sequencing and expression of a cDNA encoding mammalian valyl-tRNA synthetase. , 1993, Gene.

[3]  Paul Schimmel,et al.  Mutational separation of two pathways for editing by a class I tRNA synthetase. , 2002, Molecular cell.

[4]  R. Kopito,et al.  Impairment of the ubiquitin-proteasome system by protein aggregation. , 2001, Science.

[5]  M. J. Cormier,et al.  Primary structure of the Aequorea victoria green-fluorescent protein. , 1992, Gene.

[6]  W. Weigle THE INDUCTION OF AUTOIMMUNITY IN RABBITS FOLLOWING INJECTION OF HETEROLOGOUS OR ALTERED HOMOLOGOUS THYROGLOBULIN , 1965, The Journal of experimental medicine.

[7]  Fred E. Cohen,et al.  Therapeutic approaches to protein-misfolding diseases , 2003, Nature.

[8]  C. Dobson,et al.  Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases , 2002, Nature.

[9]  D. Kirschner,et al.  Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. , 1990, Science.

[10]  Rune R. Frants,et al.  Subunits of the translation initiation factor eIF2B are mutant in leukoencephalopathy with vanishing white matter , 2001, Nature Genetics.

[11]  P. Marlière,et al.  Enlarging the Amino Acid Set of Escherichia coli by Infiltration of the Valine Coding Pathway , 2001, Science.

[12]  S. Martinis,et al.  Molecular dissection of a critical specificity determinant within the amino acid editing domain of leucyl-tRNA synthetase. , 2004, Biochemistry.

[13]  Patrick R. Griffin,et al.  Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis , 1995, Nature.

[14]  Hieronim Jakubowski,et al.  Alternative pathways for editing non-cognate amino acids by aminoacyl- tRNA synthetases , 1981, Nucleic Acids Res..

[15]  M. Snoek,et al.  The sequence and organization of the mouse valyl-tRNA synthetase gene G7a/Bat6 located in the MHC class III region , 1999, Immunogenetics.

[16]  M. Davisson,et al.  ‘Wasted’, a new mutant of the mouse with abnormalities characteristic of ataxia telangiectasia , 1982, Nature.

[17]  R. Campbell,et al.  Evidence that gene G7a in the human major histocompatibility complex encodes valyl-tRNA synthetase. , 1991, The Biochemical journal.

[18]  V. de Crécy-Lagard,et al.  Inhibited cell growth and protein functional changes from an editing-defective tRNA synthetase. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Ebel,et al.  The yeast VAS1 gene encodes both mitochondrial and cytoplasmic valyl-tRNA synthetases. , 1988, The Journal of biological chemistry.

[20]  P. Schimmel,et al.  Formation of two classes of tRNA synthetases in relation to editing functions and genetic code. , 2001, Cold Spring Harbor symposia on quantitative biology.

[21]  C. Abbott,et al.  The lethal mutation of the mouse wasted (wst) is a deletion that abolishes expression of a tissue-specific isoform of translation elongation factor 1alpha, encoded by the Eef1a2 gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  H. Trachsel Translation In Eukaryotes , 1991 .

[23]  J. Trojanowski Tauists, Baptists, Syners, Apostates, and new data , 2002, Annals of neurology.

[24]  E. Goldman,et al.  Editing of errors in selection of amino acids for protein synthesis. , 1992, Microbiological reviews.

[25]  W. M. Westler,et al.  Chemical structure of the hexapeptide chromophore of the Aequorea green-fluorescent protein. , 1993, Biochemistry.

[26]  Rachel Green,et al.  Fidelity in protein synthesis , 2005, Current Biology.

[27]  M. Sternberg,et al.  Enhanced genome annotation using structural profiles in the program 3D-PSSM. , 2000, Journal of molecular biology.

[28]  C. Carter,et al.  Cognition, mechanism, and evolutionary relationships in aminoacyl-tRNA synthetases. , 1993, Annual review of biochemistry.

[29]  S. Ackerman,et al.  Editing-defective tRNA synthetase causes protein misfolding and neurodegeneration , 2006, Nature.

[30]  A. Gow,et al.  The unfolded protein response in protein aggregating diseases , 2007, NeuroMolecular Medicine.

[31]  D Fischer,et al.  CAFASP‐1: Critical assessment of fully automated structure prediction methods , 1999, Proteins.

[32]  V. Döring,et al.  Genetic Code Ambiguity , 2002, The Journal of Biological Chemistry.

[33]  G. Bec,et al.  Reconstitution in vitro of the valyl-tRNA synthetase-elongation factor (EF) 1 beta gamma delta complex. Essential roles of the NH2-terminal extension of valyl-tRNA synthetase and of the EF-1 delta subunit in complex formation. , 1994, The Journal of biological chemistry.

[34]  D G Vassylyev,et al.  Enzyme structure with two catalytic sites for double-sieve selection of substrate. , 1998, Science.

[35]  M. Ibba,et al.  Loss of Editing Activity during the Evolution of Mitochondrial Phenylalanyl-tRNA Synthetase* , 2005, Journal of Biological Chemistry.

[36]  G. Bec,et al.  Valyl-tRNA synthetase from rabbit liver. I. Purification as a heterotypic complex in association with elongation factor 1. , 1989, The Journal of biological chemistry.

[37]  D. Perlmutter The cellular response to aggregated proteins associated with human disease. , 2002, The Journal of clinical investigation.

[38]  M. Mirande,et al.  Functional Interaction of Mammalian Valyl-tRNA Synthetase with Elongation Factor EF-1α in the Complex with EF-1H* , 1999, The Journal of Biological Chemistry.

[39]  Roger Y. Tsien,et al.  Improved green fluorescence , 1995, Nature.

[40]  S. Yokoyama,et al.  Structural Basis for Non-cognate Amino Acid Discrimination by the Valyl-tRNA Synthetase Editing Domain* , 2005, Journal of Biological Chemistry.

[41]  J. Thevelein,et al.  Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy , 2006, Nature Genetics.

[42]  J. Sambrook,et al.  Protein folding in the cell , 1992, Nature.

[43]  E. Wang,et al.  Characterization of Elongation Factor-1A (eEF1A-1) and eEF1A-2/S1 Protein Expression in Normal and wasted Mice* , 2001, The Journal of Biological Chemistry.

[44]  William E. Balch,et al.  Integration of endoplasmic reticulum signaling in health and disease , 1999, Nature Medicine.

[45]  D. Yang,et al.  Mammalian high molecular weight and monomeric forms of valyl-tRNA synthetase. , 1988, Biochemistry.

[46]  Paul Schimmel,et al.  Elucidation of tRNA‐dependent editing by a class II tRNA synthetase and significance for cell viability , 2003, The EMBO journal.

[47]  M. S. van der Knaap,et al.  Leukoencephalopathy With Vanishing White Matter: From Magnetic Resonance Imaging Pattern to Five Genes , 2003, Journal of child neurology.

[48]  S. Zimmer,et al.  Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. , 2000, Anticancer research.

[49]  Sunghoon Kim,et al.  Human lysyl-tRNA synthetase is secreted to trigger proinflammatory response. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[50]  N. Sonenberg,et al.  Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap , 1990, Nature.

[51]  T. Fukuchi-Shimogori,et al.  Malignant transformation by overproduction of translation initiation factor eIF4G. , 1997, Cancer research.

[52]  D. Söll,et al.  Aminoacyl-tRNA synthesis. , 2000, Annual review of biochemistry.

[53]  A. Steinmetz,et al.  Transfer RNAs and aminoacyl-tRNA synthetases in plant organelles. , 1980 .

[54]  P. Schimmel,et al.  Mutational analysis suggests the same design for editing activities of two tRNA synthetases. , 1996, Biochemistry.

[55]  P. Lansbury,et al.  Amyloid diseases: abnormal protein aggregation in neurodegeneration. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[56]  P. Schimmel,et al.  Transfer ribonucleic acid synthetase catalyzed deacylation of aminoacyl transfer ribonucleic acid in the absence of adenosine monophosphate and pyrophosphate. , 1972, Biochemistry.

[57]  P. Marlière,et al.  Artificially ambiguous genetic code confers growth yield advantage. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[58]  John Q Trojanowski,et al.  ‘Unfolding’ pathways in neurodegenerative disease , 2003, Trends in Neurosciences.

[59]  R. Kaufman Orchestrating the unfolded protein response in health and disease. , 2002, The Journal of clinical investigation.

[60]  W. Weigle TERMINATION OF ACQUIRED IMMUNOLOGICAL TOLERANCE TO PROTEIN ANTIGENS FOLLOWING IMMUNIZATION WITH ALTERED PROTEIN ANTIGENS , 1962, The Journal of experimental medicine.

[61]  M. Tuite,et al.  The non‐standard genetic code of Candida spp.: an evolving genetic code or a novel mechanism for adaptation? , 1997, Molecular microbiology.

[62]  S Falkow,et al.  FACS-optimized mutants of the green fluorescent protein (GFP). , 1996, Gene.

[63]  Roland L. Dunbrack,et al.  Comparative modeling of CASP3 targets using PSI‐BLAST and SCWRL , 1999, Proteins.

[64]  P. Schimmel,et al.  Residues in a class I tRNA synthetase which determine selectivity of amino acid recognition in the context of tRNA. , 1995, Biochemistry.

[65]  C. Kurland,et al.  Translational accuracy and the fitness of bacteria. , 1992, Annual review of genetics.

[66]  R B Loftfield,et al.  The frequency of errors in protein biosynthesis. , 1972, The Biochemical journal.

[67]  M. Yarus Phenylalanyl-tRNA synthetase and isoleucyl-tRNA Phe : a possible verification mechanism for aminoacyl-tRNA. , 1972, Proceedings of the National Academy of Sciences of the United States of America.

[68]  Paul Schimmel,et al.  Incorporation of nonnatural amino acids into proteins. , 2004, Annual review of biochemistry.

[69]  A. N. Baldwin,et al.  Transfer ribonucleic acid-induced hydrolysis of valyladenylate bound to isoleucyl ribonucleic acid synthetase. , 1966, The Journal of biological chemistry.

[70]  T. Steitz,et al.  Insights into editing from an ile-tRNA synthetase structure with tRNAile and mupirocin. , 1999 .

[71]  C. Anfinsen Principles that govern the folding of protein chains. , 1973, Science.

[72]  A. Wolfson,et al.  Purification and properties of a high-molecular-mass complex between Val-tRNA synthetase and the heavy form of elongation factor 1 from mammalian cells. , 1991, European journal of biochemistry.

[73]  K. Fischbeck,et al.  Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V. , 2003, American journal of human genetics.